Published Papers
In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population
Accelerating Development of Benziamidazole-Class ProtonPump Inhibitors A Mechanism-Based PKPD Model toOptimize Study Design with Ilaprazole as a Case Drug
Application of Physiologically‑Based Pharmacokinetic Modeling in Drug‑Drug Interaction Prediction
Model-Guided Drug Discovery: Development History and Application Thinking
Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1−4 by Virtual Bioequivalence Model
Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers
PBPK modeling to predict drug‑drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
Related Publications
Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol)
Prediction of pharmacokinetic / pharmacodynamic properties of aldosterone synthase inhibitors at drug discovery stage using an artificial intelligence‑physiologically based pharmacokinetic model.
Predicting Drug‑Drug Interactions Involving Rifampicin Using a Semi‑mechanistic Hepatic Compartmental Model.
Predicting pharmacodynamic effects through early drug discovery with artificial intelligence‑physiologically based pharmacokinetic (AI‑PBPK) modelling.
Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling.
Predicting the Pharmacokinetics of Orally Administered Drugs across BCS Classes 1‑4 by Virtual Bioequivalence Model.
In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.
Accelerating Development of Benziamidazole‑Class Proton Pump Inhibitors: A Mechanism‑Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug.
In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.
Semi‑PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC‑01(Varenicline) Nasal Spray.
Quantifying Induction/ Inhibition Effects on Fuzuloparib Using a Physiologically Based Pharmaco‑Kinetic (PBPK) model.
Predicting Fluconazole Drug‑Drug Interactions Using a Physiologically‑based Pharmacokinetic (PBPK) Model.
B²O Pharma is an innovative pharmaceutical R&D enterprise focusing on AI‑enabled clinical pharmacology and quantitative pharmacology, committed to advancing model‑informed drug development.